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Infection History Determines Susceptibility to
Unrelated Diseases
Nikolas Rakebrandt and Nicole Joller*
Epidemiological data suggest that previous infections can alter an individual’s
susceptibility to unrelated diseases. Nevertheless, the underlying mechanisms
are not completely understood. Substantial research eﬀorts have expanded the
classical concept of immune memory to also include long‐lasting changes in
innate immunity and antigen‐independent reactivation of adaptive immunity.
Collectively, these processes provide possible explanations on how acute
infections might induce long‐term changes that also aﬀect immunity to
unrelated diseases. Here, lasting changes the immune compartment undergoes
upon infection and how infection experience alters the responsiveness of
immune cells towards universal signals are reviewed. This heightened state of
alert enhances the ability of the immune system to combat even unrelated
infections but may also increase susceptibility to autoimmunity. At the same
time, infection‐induced changes in the regulatory compartment may dampen
subsequent immune responses and promote pathogen persistence. The
concepts presented here outline how infection‐induced changes in the immune
system may aﬀect human health.
1. Introduction
People react diﬀerently to immunological challenges, such as
infections or cancer, and show large variance in their susceptibility
to inﬂammatory diseases, such as allergies or autoimmunity. The
responsiveness of the immune system is naturally to a large degree
determined by genetic factors. However, a series of recent studies
have revealed that genetic factors can only explain about 50–75% of
the immune trait variance and the immune proﬁle of an individual
is thus to an astonishingly large degree determined by environ-
mental factors.[1,2] There is robust epidemiologic evidence that the
decreasing frequency of infections in devel-
oped countries correlates with a rising
prevalence of allergies and other inﬂamma-
tory disorders, as already put forward in the
hygiene hypothesis almost 30 years ago.[3]
The hypothesis has since been expanded and
adapted to account also for the rise in
autoimmunity in developed countries.[4] In-
deed, reduced incidence of infections and
lower microbiotic diversity in developed
countries correlate with an increased pre-
valence of clinical conditions that are caused
by inappropriate immune responses, such as
allergy and autoimmunity—and possibly
even cancer.[5] These data indicate that both
pathogenic and nonpathogenic microorgan-
isms play a fundamental role in educating
the immune system.[6] While the speciﬁc
mechanisms regulating how the immune
response to one pathogen alters the response
to a later infection with another pathogen or
the susceptibility to autoimmunity, allergy, or
cancer have been studied in some individual
combinations, a global picture of how infection history aﬀects
disease susceptibility is still lacking.
Twin studies have been used to determine heritable versus
nonheritable inﬂuences in immune responses elicited by
vaccinations and the development of autoimmune diseases and
found that both aspects strongly aﬀect the immunological status
of an individual.[7] The microbes (commensal and pathogenic) an
individual encounters throughout his or her life are most likely a
major determinant for the nonheritable factors. Indeed mono-
zygous twin pairs, from which only one twin acquired
cytomegalovirus (CMV) infection, show greatly enhanced varia-
tion for immune parameters after the infection.[1] Chronic
infections, like CMV, and continuous interactions with com-
mensal microbiota thus shape the immune system. Intriguingly,
accumulating evidence suggests that transient challenges, such
as acute infections and vaccinations, also have nonspeciﬁc eﬀects
on the ability of the immune system to react to other diseases.[8,9]
Several adaptations of the immune system that could contribute
to this altered reactivity have been reported, which include
changes in the innate and adaptive arm of the immune system as
well as alterations in its regulatory mechanisms. The following
sections illustrate the long‐term changes that pathogen encoun-
ters elicit in these diﬀerent parts of the immune system
(Figure 1), how the sum of these changes contributes to shaping
the immune system over time and how this may aﬀect
susceptibility to unrelated diseases.
© 2019 The Authors. BioEssays Published by WILEY Periodicals, Inc. This
is an open access article under the terms of the Creative Commons
Attribution‐NonCommercial‐NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited,
the use is non‐commercial and no modiﬁcations or adaptations
are made.
Dr. N. Rakebrandt, Prof. N. Joller
Institute of Experimental Immunology
University of Zurich
Winterthurerstrasse 190
CH‐8057, Zurich, Switzerland
E-mail: nicole.joller@immunology.uzh.ch
DOI: 10.1002/bies.201800191
The ORCID identiﬁcation number(s) for the author(s) of this article
can be found under https://doi.org/10.1002/bies.201800191.
BioEssays 2019, 41, 1800191 1800191 (1 of 12) © 2019 The Authors. BioEssays Published by WILEY Periodicals, Inc.
2. Infection‐induced Changes in the Immune
System
2.1. Infections Generate Pathogen‐Speciﬁc and Heterologous
Immunity
The capability to memorize previous pathogenic encounters
and thereby confer superior protection if the same pathogen
is re‐encountered represents a well‐established core feature
of the vertebrate adaptive immune system. Memory T cells
can rapidly re‐expand and are activated upon engagement of
their cognate antigen with their T‐cell receptor (TCR).
Antibody production by memory B cells furthermore
contributes to rapid and more robust responses upon re‐
encounter with a speciﬁc pathogen. Although these mechan-
isms constitute the basis for vaccinations, early observations
have noted that certain vaccines such as Bacillus Calmette‐
Guérin (BCG), which protects against tuberculosis, can
improve overall childhood survival.[10] These observations
have hinted that the immune system cannot only learn to
defend its host against re‐encounter with the same pathogens
but might also become superior in ﬁghting other, unrelated
pathogens under certain circumstances. To date, a number of
mechanisms have been described that are believed to
contribute to heterologous immunity (Table 1). These
include cross‐reactivity and bystander activation of T cells
as well as trained immunity of innate immune cells. A
general feature of innate and adaptive immune cells that
have participated in an immune response is an altered
epigenetic landscape.[28,29] These alterations could put them
in a “poised state” and add an additional layer of responsive-
ness towards inﬂammatory cues, such as cytokines and the
engagement of germline‐encoded receptors, during hetero-
logous immune challenges. To date, a number of studies
have shown how mechanisms of heterologous immunity can,
on the one hand, contribute to protection against newly
encountered infections of their host but, on the other hand,
pose a potential risk for immunopathology or the establish-
ment of autoimmune disorders.
2.2. How Selective Are Adaptive Immune Cells?
The most striking feature of T cells and antibodies produced by
B cells is their unique speciﬁcity for their cognate antigen. This
enables the formation of immunological memory, directed
responses, and protects from the emergence of autoreactive T
cells. But just how speciﬁc are T cells and antibodies really?
About two decades ago, Mason[30] argued that cross‐reactivity of
the TCR is required for robust immunological protection. He
supported this hypothesis with a simple but conclusive model,
in which the number of monospeciﬁc naïve T cells required to
cover all possible foreign peptides would be impossible to
generate and maintain in a physiological context. Indeed, cross‐
reactivity has emerged as a common, or even necessary, feature
of T cells and antibodies with potentially beneﬁcial and adverse
consequences for the host.[31]
Whether a T cell or an antibody cross‐reacts with diﬀerent
antigens is determined by the sequence and structural
similarities of these antigens. Such similarities, also known as
molecular mimicry, can occur between self‐ and foreign
antigens.[32] Importantly, molecular mimicry can result in
autoimmunity through inappropriate responses of cross‐
reactive T cells that were primed during microbial encounters
and are subsequently activated by recognition of self‐anti-
gens.[32,33] Conversely, T‐cell clones with a strong aﬃnity
towards a speciﬁc self‐antigen will be deleted during their
maturation process and thereby the T‐cell pool responsive
towards a similar microbial or tumor antigen might be
reduced.[34]
In addition to this, cross‐reactivity towards diﬀerent foreign
antigens was also frequently observed in subsequent infections
with related but also unrelated viruses. Some studies have
shown that cross‐reactive memory T‐cell clones can be favored
over non‐cross‐reactive clones during heterologous infections,
thereby altering the relative contributions of diﬀerent T‐cell
clonotypes, also known as immunodominance (Figure 2).[35] In
extreme cases this could skew the immune response towards
cross‐reactive epitopes and thereby facilitate viral escape by
mutation of the respective epitope.[36] Although cross‐reactive
memory T cells could help to confer protective immune
Figure 1. Overview of the impact of infection‐induced adaptations of the
immune system. Infections induce numerous speciﬁc and unspeciﬁc
alterations in the composition and function of immune cells. These in-
clude induction of memory cells, cross‐reactivity, bystander activation of
T cells, and trained immunity of innate cells as well as changes in Treg
abundance and composition. Each of these eﬀects can, on the one hand,
inﬂuence the ability of the immune system to ﬁght and clear subsequent
infections and may, on the other hand, promote tissue tolerance or
inﬂammation.
Table 1. Impact of infection‐induced adaptations of the immune system
on heterologous protection.
Process
Protection against heterologous
infection Reference
Memory
Cross‐reactivity [42–44], [46] or [36], [45]
Bystander activation [57], [58]
Trained immunity [13–15]
Microbiota/chronic
infection
[61–63] or [73]
Physical remodeling [9], [64]
Tregs [73–75]
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responses towards unrelated pathogens, they also pose a risk
for immunopathology.[37,38] This is showcased by a study, in
which lymphocytic choriomeningitis virus (LCMV)‐immune
mice were challenged with inﬂuenza A virus (IAV) infection
and the degree of IAV‐speciﬁc T cells cross‐reacting with
LCMV‐peptides correlated with the degree of lung injury.[39]
Several studies have also found evidence for the signiﬁcance
of cross‐reactive T cells in human infectious diseases. Epstein–
Barr virus (EBV) is a common infection in humans and well
known as the causative agent of infectious mononucleosis (IM).
IM involves pronounced activation and proliferation of CD8+ T
cells and can vary considerably in severity. T‐cell clones
recognizing IAV epitopes were identiﬁed among the T cells
activated during IM.[40] Moreover, the frequency of IAV and
EBV cross‐reactive CD8+ T cells was reported to correlate with
disease severity during IM.[41] Conversely, a more recent study
suggested that some IAV‐speciﬁc T‐cell clones might be
protective against infection with EBV.[42] These contrasting
results highlight that the relationship between cross‐reactive
T cells and the outcome of heterologous infections may be very
complex and not only depend on the respective pathogens but
also on the speciﬁc cross‐reactive antigens or T‐cell clones.
Antibodies and T cells are also commonly cross‐reactive to
diﬀerent species of ﬂavivirus, including the Zika virus (ZIKV)
and the dengue virus (DENV). CD8+ T cells from DENV‐
immune mice can contribute to immunity against experimental
ZIKV infection.[43] In line with these reports, a stronger T‐cell
response and altered immunodominance pattern were also
observed in DENV‐pre‐exposed patients upon ZIKV infec-
tion.[44] In contrast to the potentially protective role of cross‐
reactive CD8+ T cells, several publications have indicated that
cross‐reactive antibodies from DENV‐exposed humans or mice
A
B
C
D
Figure 2. Cross‐reactive T‐cell clones can inﬂuence the outcome of heterologous infections. A) During an infection, T cells speciﬁc for pathogen
antigens will proliferate and contribute to pathogen clearance. Diﬀerent T‐cell clones recognizing various antigen epitopes will respond, some
showing more dominance than others. B) Memory T cells that diﬀerentiated during a previous acute infection may be cross‐reactive for antigens of an
unrelated pathogen. These cross‐reactive memory T cells harbor the potential to expand and produce cytokines in response to a heterologous
challenge. C) Activation of cross‐reactive memory T cells could facilitate faster pathogen clearance during the secondary infection. D) If the immune
response is strongly shifted towards the cross‐reactive T‐cell clone, this can lead to adverse eﬀects. Extreme immunodominance of one epitope might
facilitate the emergence of viral escape mutants or excessive immune responses could lead to immunopathology.
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can enhance ZIKV infection.[45] Thus, it is exceedingly diﬃcult
to dissect and determine the overall contribution of previous
DENV exposure to infection with ZIKV or disease pathogen-
esis. Nevertheless, a recent epidemiological study of local
residents in Brazil found that previous exposure to DENV is
associated with a lower risk of ZIKV infection.[46]
Overall, the evidence for protective functions of cross‐
reactive T cells or antibodies in humans is still rare. This does
not seem surprising, as it would likely not result in any clinical
symptoms. However, memory‐phenotype CD4+ T cells with
speciﬁcities for human immunodeﬁciency virus (HIV), CMV,
and herpes simplex virus (HSV) have been found in the blood
of donors who were never infected with these viruses.[16] The
same study also showed that IAV‐speciﬁc T cells that expanded
in individuals following ﬂu vaccination were able to recognize
other microbial peptides, thus indicating that vaccinations
could induce long‐lived T cells that cross‐react with peptides
derived from unrelated pathogens.
2.3. Training Shapes Innate Immunity
The long‐standing dogma that memory features can only be
acquired by adaptive immune cells has been overthrown by a
number of studies within the last decade. Innate immune cells
such as natural killer cells (NK cells) and myeloid cells can also
form a type of memory that has been termed “trained
immunity.”[47] For instance, NK cells that were preactivated
had a higher cytokine response upon reactivation.[48] Further-
more, preactivated NK cells showed higher proliferative capacity
than nonactivated controls and could thereby maintain
enhanced function.[49] Importantly, it was demonstrated that
preactivation of NK cells can enable them to respond more
potently towards tumor cells.[50] In contrast to other innate cells,
NK cells are also able to form antigen‐dependent memory by
expression of the germline‐encoded receptor Ly49H, which
speciﬁcally recognizes a mouse cytomegalovirus (MCMV)‐
encoded glycoprotein.[51] Through this mechanism, MCMV‐
speciﬁc NK cells can generate a pool of long‐lived memory cells.
Myeloid cells are also able to acquire a “trained” phenotype,
which enables them to respond more eﬃciently to inﬂamma-
tory stimuli. Trained monocytes were able to confer protection
from reinfection with the opportunistic fungal pathogen
Candida albicans in mice lacking adaptive immune cells.[11]
This study also showed that β‐glucans, a component of the
fungal cell wall, could train the monocytes and induced changes
in their histone methylation. Indeed, epigenetic changes have
been shown to be a hallmark of trained monocytes.[28] Training
of monocytes could also contribute to a potential heterologous
protection through BCG vaccinations, which has been fre-
quently discussed.[12] In a study addressing this hypothesis,
monocytes from BCG‐vaccinated donors acquired epigenetic
modiﬁcations and exhibited higher functional responsiveness
to heterologous inﬂammatory stimuli when compared to
monocytes that were collected before vaccination.[13] Further-
more, a BCG vaccination trial in humans showed that
epigenetic remodulation of monocytes correlated with cross‐
protection against experimental yellow fever virus (YFV)
challenge.[14]
Diﬀerent functional states in immune cells are accompanied
and supported by changes in cell metabolism.[17] In accordance
with this observation, metabolic and epigenetic changes
associated with trained immunity are closely interlinked.
BCG‐induced trained immunity in monocytes is dependent
on alterations of cellular metabolism, most notably the
induction of glycolysis.[18] More evidence for the connection
between trained immunity and metabolism was provided by a
recent study, which showed that the metabolite mevalonate can
induce trained immunity in monocytes.[19] Because monocytes
are rather short‐lived cells, the question arose whether their
precursor cells in the bone marrow might acquire a diﬀerent
phenotype through immune training and thereby inﬂuence
myelopoiesis. A combination of three studies approaching the
subject with diﬀerent murine models of immune
training—β‐glucan administration, BCG vaccination, and
sterile inﬂammation induced by a high‐fat western diet—all
found that the hematopoetic precursors of myeloid cells were
modiﬁed and thereby constitute an important component of
trained immunity.[20]
However, trained immune cells may also be detrimental to
host ﬁtness in certain settings and contribute to disease
manifestation. Monocytes isolated from patients with sympto-
matic atherosclerosis showed epigenetic modiﬁcations and
expression levels of glycolytic enzymes that could be attributed
to trained immunity.[15] Innate immune cells in the brain can
also acquire a trained state and thereby aﬀect central nervous
system inﬂammation. In mice, inﬂammation‐mediated mod-
ulation of brain‐resident macrophages (microglia) aﬀected
neuropathology in diseases like an experimental Alzheimer’s
model.[52] Interestingly, the authors of the latter study found
pronounced, microglia‐dependent diﬀerences in brain cytokine
content depending on the administration of the inﬂammatory
stimulus. Repeated injection resulted in a tolerant state,
whereas a single administration was connected to a training
eﬀect and therefore a lower threshold for activation. This
highlights the ability of the innate immune system to adapt to
diﬀerent kinds of stimuli and thereby provides important
insights for the design of immunotherapies.
2.4. T Cells Show Unexpected Talents
As previously mentioned, T cells express a TCR that is
unique for each clonotype and can recognize its cognate
antigen in the context of MHC presentation. Two additional
signals are required in order to direct the T cell to an
appropriate response or diﬀerentiation: the engagement of
costimulatory receptors and signals provided by cytokines.
However, depending on the diﬀerentiation status of T cells,
they can also be activated independent of TCR stimulation
and therefore respond in a nonspeciﬁc manner during a
heterologous immune challenge. This phenomenon has
been termed “bystander” or “innate‐like” activation of T
cells. While TCR‐dependent activation of T cells is rather
well described, the understanding of T‐cell activation by
cytokines or germline‐encoded receptors without recognition
of cognate antigen is still quite limited.
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The ﬁrst observations that memory‐phenotype CD8+ T cells
can be activated by cytokines in the absence of TCR signaling were
already made about 20 years ago. In particular, the proliferation of
memory‐phenotype CD8+ T cells in mice could be induced with
cytokine interleukin‐15 (IL‐15).[53] Some groups that observed
bystander activation or proliferation of T cells have argued that the
biological relevance would be rather minimal.[54] Although this
may be true for the models used in the respective studies, other
groups have argued for a signiﬁcant contribution of bystander
T cells in various settings. It has become clear that innate‐like
activation of memory T cells depends on a number of variables
like the cytokine environment, tissue homing or residency, and
ligand expression of other cells, which are likely not met by all
commonly examined virus infections or inﬂammation models.
Importantly, the cytokine proﬁle that is induced by innate cells
during a heterologous challenge needs to ﬁt the requirements for
innate‐like activation of T cells. Some cytokines, in particular
IL‐12, IL‐18, or IL‐15, were shown to potently induce interferon‐γ
(IFN‐γ) production or cytolytic activity in memory CD8+ T cells.[55]
In mouse models, activation of memory CD8+ T cells in an
antigen‐independent manner contributed to protection against
heterologous infection with Listeria monocytogenes.[56] In addition
to cytokines, engagement of germline‐encoded receptors can also
contribute to TCR‐independent activation of memory CD8+
T cells. Such receptors can be expressed by innate as well as
adaptive immune cells and detect a wide range of signals that are
associated with infections or malignant cells. Some adaptive
immune cells can also be activated in the absence of their cognate
antigen through the recognition of these general signals in
combination with cytokine stimuli. NK receptors like NKG2D are
broadly expressed on memory CD8+ T cells in mice and humans.
Antigen‐independent activation of memory T cells through
NKG2D engagement could have beneﬁcial eﬀects for early
pathogen control and thereby support innate immunity.[57] In
contrast to this protective role, engagement of NKG2D in
bystander memory T cells may also result in immunopathology
under certain conditions, as shown in the context of Leishmania
major infection in mice.[58] In humans, NKG2D engagement on
CD8+ T cells is thought to contribute to immunopathology in
celiac disease.[25] Furthermore, a recent report described how
TCR‐independent activation of memory CD8+ T cells by IL‐15
and NK‐receptor engagement might signiﬁcantly contribute to
liver injury in patients during acute hepatitis A virus infection.[26]
Overall, these ﬁndings reveal that innate‐like activation of
bystander T cells might have a signiﬁcant impact on disease
outcome depending on the inﬂammatory context (Figure 3). It
has become clear that cytokines released by innate cells and
engagement of NK receptors can trigger TCR‐independent
activation of memory or eﬀector T cells and thereby add an
additional layer to the immune response. Nevertheless, many
important questions concerning this mode of T‐cell activation
remain to be answered: for instance, which speciﬁc T‐cell
subsets can be activated independent of antigen recognition.
2.5. Microbe Exposure Shapes the Immune System
The human body is not just challenged by infections; it is also
colonized by a diverse collection of viruses, as well as the
microbiota, which is composed of microorganisms like bacteria,
fungi, and protists. The microbiota mostly resides at barrier sites
such as the skin or the gut and plays an important role in training
and shaping the host immune system, allowing for induction of
protective immunity to combat infections but also the establish-
ment of immune tolerance.[59] However, changes in the micro-
biota composition or diversity induced by hygiene conditions,
A B
C
Figure 3. TCR‐independent activation of T cells. A) NKG2D‐expressing memory CD8+ T cells can be activated by IL‐15 and expression of NKG2D
ligands on transformed or infected cells. B) Some cytokines activate memory CD8+ T cells in the absence of TCR signaling. C) Both of these
mechanisms can lead to the secretion of IFN‐γ or cytotoxic molecules like perforin and granzymes. This can confer protection against heterologous
pathogens but, under some circumstances, may also lead to tissue damage.
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overuse of antibiotics, or diet can prevent the maturation and
maintenance of a healthy and balanced immune system and
predispose to inﬂammatory diseases and autoimmunity. Further-
more, depending on the context, commensal microorganisms can
become pathogenic and vice versa.[60] Microbiota as well as
ongoing chronic infections continuously condition cells of the
immune system and thereby enable a rapid response to infectious
challenges through trained immunity and bystander activation.
This is illustrated by the observation that antibiotic treatment,
which leads to a transient elimination of the bacterial microbiota,
markedly reduces the eﬃcacy of vaccinations as well as parasite‐
speciﬁc immune responses.[27] Similarly, several chronic infec-
tions were shown to enhance immune responses to unrelated
pathogens.[61] At the same time, the heightened state of alert in
persistent virus infections can also enhance immune responses
that are harmful to the host as, e.g., those causing colitis or other
inﬂammatory disorders and thus exacerbate disease.[62]
2.6. Infections Can Cause Long‐Lasting Physical Changes
In addition to changing the composition and function of
immune cells, infections often also induce physical changes in
the host that, in some cases, even persist after the infection has
been cleared. These changes can alter the microenvironment of
the aﬀected organ as outlined here for sepsis or they can induce
persisting structural changes as seen in Yersinia pseudotubercu-
losis (Y. pseudotuberculosis) infection. These changes have a large
impact on subsequent immune responses as they alter the
ability of the host to counter infections but also inﬂuence the
development of inﬂammatory disorders and therefore aﬀect
susceptibility to a broad spectrum of diseases that are not
related to the initial infectious agent.
Severe, life‐threatening infections can trigger massive
immune responses that are known as sepsis. Severe sepsis
entails multiorgan dysfunction and is often accompanied by
sepsis‐induced immunosuppression and a high risk of devel-
oping pneumonia. This immunosuppressed state persists for
weeks even after patients appear to have “recovered” from
sepsis itself.[63] A recent study revealed that the primary
infection induces lasting changes in the local microenviron-
ment in that it promotes the induction of regulatory T cells
(Tregs). These dampen the immune response and compromise
eﬀective immune responses to a secondary challenge, leaving
the host susceptible to infections.[64] This suggests that
intervention strategies that interfere with Treg induction or
function may be able to revert the generalized immune
suppression in sepsis patients and improve their survival.
Indeed, blockade of the PD‐1/PD‐L1 pathway, which interferes
with Treg function, can restore immune function and improve
survival of sepsis patients.[65] Overall, this suggests that
preceding infections induce long‐lasting changes in the local
cytokine milieu, immune cell composition, and function that
can alter the susceptibility to subsequent immune challenges.
The potent immune responses induced to rapidly eliminate the
infectious agents are often also accompanied by a certain degree of
collateral tissue damage. Once the infection is cleared, tissue
damage is usually repaired and function is restored. However, in
some instances, such as in Y. pseudotuberculosis infection,
extensive structural changes occur and persist even after the
infection is cleared.[9] Acute infection with Y. pseudotuberculosis
results in the relocation of dendritic cells that persists even beyond
the clearance of Yersinia and leads to a markedly reduced eﬃcacy
of subsequent oral vaccinations.[9] At the same time, the sustained
inﬂammation might set the stage for chronic disorders, such as
inﬂammatory bowel disease or celiac disease, which share many
features with the inﬂammation induced by Yersinia infection.[66]
Infection‐induced structural changes can thus serve as a direct
link between acute infections and the development of chronic
inﬂammatory disorders.
In both examples listed here, sepsis and Yersinia challenge,
the infection leads to long‐lasting changes in the local cytokine
milieu that can be immune suppressive or stimulating and
persists beyond the clearance of the infection. Given their
constant exposure to external challenges as well as constant
stimulation through commensals, barrier tissues might be at
particularly high risk of accumulating these kinds of immuno-
logical scars, predisposing for inﬂammatory disorders such as
inﬂammatory bowel or celiac disease, psoriasis, allergies, or
asthma but also infectious diseases such as pneumonia or
gastrointestinal infections.
2.7. Pathogen Encounter Shapes the Regulatory Immune
Response
Pathogen encounter not only initiates a proinﬂammatory immune
response to eliminate the infection, but also induces a regulatory
response that balances these eﬀects to limit immunopathology
resulting from excessive activity. At the same time, these regulatory
responses can favor pathogen persistence and chronic infections.
Myeloid suppressor cells, regulatory B cells, and Tregs are the
mediators of this regulatory response. Tregs act through diverse
mechanisms,[67] and like all T cells, are activated through the
engagement of their TCR by antigen together with costimulatory
signals.[68] However, in contrast to conventional T cells, the TCR
repertoire of Tregs is shifted towards self‐antigens.[69] This implies
that Tregs can be activated independently of foreign antigen in all
settings that enhance costimulatory signals. Once activated, their
suppressive mechanisms allow Tregs to inhibit responder T cells
irrespective of their antigen speciﬁcity, a mechanism known as
bystander suppression. Furthermore, cytokines released upon
tissue damage, such as IL‐33 and IL‐18, have been shown to be
able to activate Tregs even in the absence of a TCR signal,[70]
allowing Tregs to rapidly respond to tissue damage in a bystander
fashion and limit immune pathology by dampening the immune
response. Pathogen‐ or microbiota‐induced changes in Treg
frequency or function could therefore have a strong impact on
immune responses to heterologous challenges.
The composition of the microbiota has been shown to be a
major determinant for the induction of pro‐ versus anti‐
inﬂammatory T‐cell responses. While segmented ﬁlamentous
bacteria promote proinﬂammatory T‐cell responses and sys-
temic autoimmunity,[71] Clostridia and their metabolic
by‐products induce Tregs that have systemic suppressive eﬀects
and contribute to maintaining immune homeostasis.[72] Simi-
larly, persistent pathogens often induce an increase in Tregs
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and thereby limit the pathogen‐speciﬁc immune response,
allowing for pathogen persistence (Figure 4). This extends to all
classes of persistent pathogens, including chronic viral,
bacterial, and parasitic infections, such as tuberculosis, leprosy,
or malaria, where patients with poor anti‐pathogen responses
and persistent disease show an increase in Tregs.[73] An
extensive body of work also outlines the central role of Tregs
in parasite persistence in helminth infections and the extensive
interplay between the parasites and the immune system.[74]
Importantly, the generalized suppression of immunity by
helminth‐induced Tregs also extends to modulation of un-
related immune responses, as helminth‐infected patients show
reduced immune responses towards childhood vaccines or
other parasites.[75] Given that coinfections with helminths and
malaria and/or tuberculosis are still frequent in many low‐
income countries, it will be important to determine whether the
immune‐suppressive eﬀect of pathogen‐induced Tregs con-
tinues to increase with increasing infectious burden and how
this could be counteracted to allow for pathogen clearance and
eﬃcient vaccination strategies against prevalent diseases.
Interestingly, the high levels of parasitic infections in low‐
income countries also seem to have beneﬁcial eﬀects in that
inﬂammatory and autoimmune disorders are much less frequent
than in the developed world.[74] In a cohort of Argentinian
multiple sclerosis patients, individuals who unintentionally
acquired a helminth infection displayed elevated Treg frequen-
cies and remission from the symptomatic disease. This was
reversed upon anti‐helminth treatment and accompanied by a
loss of the regulatory response and clinical relapse.[21] These
ﬁndings could also be recapitulated in experimental animal
models where helminth infection protects mice from inﬂamma-
tory disorders such as celiac disease and allergy and this
protection can be transferred to naïve animals via Treg
transfer.[22] These ﬁndings have led to therapeutic approaches
in clinical trials that capitalize on the ability of parasite extracts to
induce Tregs and thereby dampen inﬂammatory immune
responses. The stimulation of Treg activity has thus emerged
as a central concept that explains the beneﬁcial eﬀects of certain
microbiota and parasitic infections in ameliorating inﬂammatory
diseases such as allergy and autoimmune disorders as well as
improving transplantation tolerance.[23]
Recent research has also revealed that Tregs themselves
represent a mixture of functionally diverse subsets. Further-
more, infectious challenges can transiently alter the composi-
tion and function of Tregs to allow for the induction of anti‐
pathogen responses but also eﬃciently shutting down the
eﬀector response once the infection has been cleared
(Figure 4).[24] Most likely, these temporary changes in Treg
composition not only aﬀect immune responses against the
ongoing infection but also would alter suppression of
autoreactive immune cells or cells speciﬁc for persistent
pathogens. Indeed, epidemiological data revealed that several
autoimmune diseases show a correlation with certain patho-
gens, although these do not induce the disease. In the case of
multiple sclerosis, many diﬀerent viruses were investigated as a
possible cause, most recently EBV. However, there is no proof
Figure 4. Impact of acute and chronic infections on immune cell composition and function. At steady state the body is colonized by commensals and
a balanced immune composition is maintained (middle). Chronic infections by viruses, bacteria, or parasites lead to a dominance of regulatory T cells
(Tregs) and as a consequence suppress the eﬀector response and immunity (left). Acute infections induce the expansion of eﬀector cells, which
mediate pathogen clearance and immunity, as well as changes in the Treg composition (right). Overall, these changes in immune cell composition
and function aﬀect the long‐term responsiveness of the immune system and its ability to react to immune challenges.
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that any of them causes multiple sclerosis.[76] Similarly, there is
a strong correlation between enterovirus species and type 1
diabetes, but again, there is no indication that the virus can
actually cause islet destruction.[77] As such, the viral infections
that are associated with the diseases likely serve as their
environmental triggers without being the causative agent. We
propose that in addition to infection‐induced training of innate
immunity, bystander activation of memory cells and reactiva-
tion of cross‐reactive lymphocytes, changes in Treg composi-
tion and function may allow an autoreactive immune response
to unfold and thus contribute to the manifestation of
autoimmune diseases. In contrast, infection‐induced changes
in Treg composition could also result in a more potent
suppression of immune responses and thereby promote
pathogen or tumor persistence.
2.8. Speaking the Same Language—Educated Immune Cells
Respond to Universal Signals
As outlined in the preceding sections, infections trigger long‐
lasting changes in both the innate and adaptive arm of the
immune system that go far beyond classical memory. Infection
experience seems to equip both types of immune cells with an
altered responsiveness towards two types of universal signals:
cytokines and the ligation of germline‐encoded receptors. Innate
cells are thus able to respond more quickly and potently as
observed in trained immunity. Adaptive immune cells are able to
rapidly participate in an immune response even in the absence of
their cognate antigen as observed in bystander activation.
Following infection, immune cells adopt a state of alertness that
persists even beyond pathogen clearance and is maintained by
epigenetic modiﬁcations.[28,29] This education of the immune
system likely re‐enforces a ﬁrst line of defense in heterologous
challenges and thereby reduces the magnitude of the immune
response required to control the secondary infection and allows
the host to preserve its resources. In addition, this heightened
responsiveness might serve as a means to compensate for the loss
of clonal diversity that is observed with age and contributes to the
higher susceptibility of older people to infections.[78] Indeed, a
recent study found that the eﬀect of non‐heritable factors on the
immune response becomes more dominant with age, most likely
due to the accumulating eﬀect of environmental inﬂuences.[1,79]
Interestingly, the frequency of Tregs was more strongly
Table 2. Potential impact of primary acute infections on immune cell activation during heterologous immune responses.
Branch Cell type Mechanisms Possible disease associations
Potential impact
on host
Innate Macrophages ● Epigenetic changes in
progenitor cells
●Heterologous protection[13], [14] Beneﬁcial
● Proinﬂammatory phenotype ●Neuropathology[52] Harmful
● Enhanced responsiveness ● Atherosclerosis[15]
NK cells ● Cytokine‐induced epigenetic
changes
● Antitumor responses[50] Beneﬁcial
● Cytokine production ●Heterologous protection?
● Cytotoxicity ● Tissue damage? (mechanism may be similar to
memory bystander CD8+ T cells)
Harmful
Granulocytes ● Epigenetic changes in
progenitor cells?
●Heterologous protection? Beneﬁcial
● Allergic disease? Harmful
Mast cells ● Epigenetic changes? ●Heterologous protection? Beneﬁcial
● Allergic disease? Harmful
Adaptive Eﬀector and memory CD8+
T cells
● Epigenetic changes ●Heterologous protection[56], [57] Beneﬁcial
● Cytokine production ● Antitumor responses?
● Cytotoxicity ● Tissue damage[25], [26], [58] Harmful
Eﬀector and memory CD4+
T‐helper cells
● Epigenetic changes ●Heterologous protection? Beneﬁcial
● Cytokine production ● Autoimmunity? Harmful
Regulatory ● Epigenetic changes? ● Tissue protection? Beneﬁcial
T cells ● Tissue abundance? ● Immune homeostasis?
● Enhanced responsiveness? ● Promoting pathogen persistence? Harmful
●Hampered antitumor responses?
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determined by environmental factors with progressing age,[1]
suggesting that infection‐induced changes in Treg frequencies
and function might be an important factor in shaping the
immune response and determining susceptibility to infectious
and inﬂammatory diseases.
Trained immunity and bystander activation both show positive
eﬀects on pathogen control and maybe even anti‐cancer immunity
as outlined above (Table 2).[50] At the same time, heterologous
immunity can also have negative consequences for the host such
as increased tissue damage as seen in hepatitis[26] and likely also
contributes to disease in the context of autoimmunity. Most of the
changes observed in an experienced immune system reported to
date result in enhanced inﬂammatory responses and increased
cytotoxicity (through NK and cytotoxic T cells). Whether similar
mechanisms also exist in cells contributing to allergic responses or
anti‐helminth immunity, such as mast cells, eosinophils, or
T helper cells, remains to be determined (see Table 2). Similarly,
how cells participating in a heterologous response are regulated is
still completely unclear. While Tregs have been shown to have
tissue protective eﬀects upon antigen‐independent activation,[70] it
is unclear which cell type might dampen and limit heterologous
immunity to prevent immune pathology. Although many ques-
tions still remain open, recent developments have made it clear
that immune cells are more versatile than previously appreciated.
In addition to their classical functions, infection‐experienced
immune cells rapidly respond to stimulation by cytokines or
germline‐encoded receptors and initiate potent heterologous
immune responses that contribute to pathogen control but might
also enhance immune pathology.
3. Conclusions and Outlook
The concepts presented here outline how pathogens and
commensals induce long‐term changes in the immune system
that aﬀect subsequent immune responses and impact human
health. Animal models and clinical studies show that vaccina-
tions, prior infections, or coinfections can modify the immune
response to unrelated pathogens. Additionally, a number of
inﬂammatory diseases have been linked to infections but ﬁnding
direct associations between pathogens and the initiation of these
disorders has remained diﬃcult. This might in part be due to the
fact that infections can induce long‐term changes in the immune
system that may persist even once the infection is cleared. These
eﬀects likely accumulate over time and the onset of inﬂamma-
tory disease does not have to coincide with the infectious trigger
(s). Similarly, infection history can also induce changes that
enhance the regulatory properties of the immune system and
thus favor the establishment of chronic infections and prevent
protective immunity against cancer. Future work should be
aimed at further unraveling the mechanistic basis for these
changes in the immune system and most importantly also at
bringing these concepts together to reveal a more comprehensive
picture of the mechanisms underlying heterologous immunity.
Each new infection or immune trigger an individual is
exposed to during a lifetime will educate and potentially alter the
dynamics of their immune system and it is important that this is
taken into account in preclinical models. Future research should
identify the factors that shape the immune system in these
processes and determine how heterologous secondary immunity
aﬀects vaccine eﬃciency and immune therapies targeting
inﬂammatory disorders or cancer to be able to optimize
preventive and therapeutic interventions in the future.
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